Schering IL-10 has "very good" efficacy, toxicity data in early clinicals, exec tells Alex. Brown.
SCHERING-PLOUGH IL-10 EFFICACY, TOXICITY DATA appear to bode well for the biosynthetic interleukin-10 product, Senior VP-Investor Relations and Corporate Communications Geraldine Foster suggested May 14 at the Alex. Brown health care seminar in Baltimore. IL-10 has had "some very good early stage trials in terms of efficacy and lack of toxicity," she said. The product is in clinicals for Crohn's disease and ulcerative colitis. IL-10 also is in early clinicals for rheumatoid arthritis.
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth